Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>M Stanley: Latest US Biosecure Act More Favorable to CN CDMO
Recommend 7 Positive 15 Negative 9 |
||||
|
||||
|
The US Senate recently passed a motion to incorporate the Biosecure Act into the National Defense Authorization Act (NDAA), according to Morgan Stanley's research report. The revised version is more moderate, allowing named companies to appeal, and has not named WUXI series companies under the biotech section. The act still needs to be jointly passed by both the Senate and the House and signed by US President Donald Trump to become law. The broker expected that shares of Chinese CDMOs will initially experience volatility, as the act appears to give the US government new tools to restrict local companies from cooperating with Chinese suppliers. However, compared to the last version blocked by the House Democrats last December, the current outcome is more favorable. Chinese CDMO stocks have risen 84% YTD, partially reflecting investors' expectations of milder geopolitical and decoupling risks. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
